Raymond James & Associates Cuts Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Raymond James & Associates reduced its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 5.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 264,392 shares of the biotechnology company’s stock after selling 13,835 shares during the period. Raymond James & Associates owned approximately 0.11% of ADMA Biologics worth $5,285,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. grew its position in ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after buying an additional 1,442,799 shares during the period. Assenagon Asset Management S.A. grew its position in ADMA Biologics by 1.1% during the second quarter. Assenagon Asset Management S.A. now owns 3,382,174 shares of the biotechnology company’s stock worth $37,813,000 after buying an additional 35,707 shares during the period. Driehaus Capital Management LLC grew its position in ADMA Biologics by 17.3% during the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock worth $33,860,000 after buying an additional 447,743 shares during the period. Mesirow Institutional Investment Management Inc. acquired a new position in ADMA Biologics during the first quarter worth about $17,221,000. Finally, Renaissance Technologies LLC grew its position in ADMA Biologics by 28.7% during the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after buying an additional 575,100 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other ADMA Biologics news, Director Jerrold B. Grossman sold 136,861 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the transaction, the director now owns 467,305 shares of the company’s stock, valued at $8,070,357.35. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 466,900 shares of company stock valued at $8,224,121. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA opened at $19.37 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The company has a market capitalization of $4.51 billion, a price-to-earnings ratio of 138.36 and a beta of 0.62. The company’s 50 day simple moving average is $17.83 and its 200 day simple moving average is $13.27. ADMA Biologics, Inc. has a 1 year low of $3.40 and a 1 year high of $21.13.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.02) earnings per share. On average, sell-side analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Analyst Ratings Changes

Several research analysts have weighed in on ADMA shares. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of ADMA Biologics in a research report on Monday, October 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.